Prostate Cancer Management Masterclass: CRPC Plenary Session 2
Prostate Cancer Management Masterclass: CRPC Plenary Session 2
Prof. Evan Yu, Assoc. Prof. Tanya Dorff
Prof. Tanya Dorff and Prof. Evan Yu present a plenary session on "Next-generation” sequencing of therapy for Castration-Resistant Prostate Cancer (CRPC).Prof. Evan Yu
Medical Oncologist
University of Washington and Seattle Cancer Care Alliance
United States (US)
Evan Y. Yu, M.D., is a medical oncologist specializing in prostate, bladder, and testicular cancer treatment and research. He graduated Alpha Omega Alpha from the University of Washington School of Medicine. He completed internal medicine residency at the Brigham and Women’s Hospital and oncology fellowship and post-doctoral training at the Dana-Farber Cancer Institute. He returned to Seattle at the end of 2004 to join the faculty at the University of Washington and Fred Hutchinson Cancer Research Center. Dr Yu is a Full Professor of Medicine and Oncology, the Clinical Research Director for GU malignancies, Core Director for the Pacific Northwest Prostate Cancer SPORE and co-PI of the DoD Prostate Cancer Clinical Trials Consortium for his institution. His research focuses on testing the next wave of novel molecular targeted therapies and immunotherapy techniques, with a complementary focus on imaging biomarkers. In addition to an active clinical and research practice, he also is the Medical Director for Clinical Research Services at the Fred Hutchinson Cancer Consortium. Previously, he served as a Hematology/Oncology Fellowship Program Director for a decade at the Fred Hutchinson Cancer Research Center. He has regularly been voted a “Top Doctor” by Castle Connolly, U.S. News and World Report, Seattle magazine, and Seattle Met magazine. He has served for many years on the National Cancer Institute Genitourinary Cancers Steering Committee and is the Co-Chair for the National Cancer Institute Prostate Cancer Task Force. Dr Yu remains active in SWOG, the Cancer Immunotherapy Trials Network and he also serves as a senior editor for Clinical Cancer Research and Uro-Today.
Assoc. Prof. Tanya Dorff
Medical Oncologist
City of Hope Comprehensive Cancer Center
United States (US)
Following a residency at Mt. Sinai Hospital in New York City, Dr Dorff came to LAC + USC Medical Center for her hematology and medical oncology fellowship. She currently heads the Genitourinary group within the Department of Medical Oncology at the City of Hope Comprehensive Cancer Center. In addition to being a devoted clinician and translational researcher, Dr Dorff has authored more than 45 peer reviewed articles as well as 35 review articles/commentaries. Dr Dorff serves as an associate editor for Clinical Genitourinary Cancer and Seminars in Urologic Oncology. She has lectured on prostate and bladder cancer treatment nationally and internationally and has presented her research at national meetings. Current research interests include the effects of fasting on chemotherapy side effects and cancer control and immunotherapy for prostate cancer. She has been the principal investigator for more than a dozen clinical trials, involving targeted therapy and immunotherapy, for genitourinary cancers.
Assoc. Prof. Tanya Dorff has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Astellas, Exelixis, Janssen and SeaGen.
Webinar |
60 min
|
Dec 2020
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
Prostate Cancer Management Masterclass: CRPC Plenary Session 2
Prof. Alicia Morgans, co-hosted, along with Dr. Neal Shore, Prof. Tanya Dorff and Prof. Evan Yu, a highly interactive GU CONNECT Virtual Masterclass on Prostate Cancer Management.
In plenary 2 Prof. Tanya Dorff and Prof. Evan Yu present “Next-generation” sequencing of therapy for Castration-Resistant Prostate Cancer (CRPC).
In plenary 1 where Dr. Neal Shore and Prof. Alicia Morgans present Paradigm shift in the management of metastatic castration-sensitive prostate cancer (mCSPC),
Watch the video and download the slides.
GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.
Other programmes of interest
Other programmes developed by Prof. Evan Yu
Prof. Evan Yu
Medical Oncologist
University of Washington and Seattle Cancer Care Alliance
United States (US)